+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cellular innate immunity and restriction of viral infection: implications for lentiviral gene therapy in human hematopoietic cells



Cellular innate immunity and restriction of viral infection: implications for lentiviral gene therapy in human hematopoietic cells



Human Gene Therapy 26(4): 201-209



Hematopoietic gene therapy has tremendous potential to treat human disease. Nevertheless, for gene therapy to be efficacious, effective gene transfer into target cells must be reached without inducing detrimental effects on their biological properties. This remains a great challenge for the field as high vector doses and prolonged ex vivo culture conditions are still required to reach significant transduction levels of clinically relevant human hematopoietic stem and progenitor cells (HSPCs), while other potential target cells such as primary macrophages can hardly be transduced. The reasons behind poor permissiveness of primary human hematopoietic cells to gene transfer partly reside in the retroviral origin of lentiviral vectors (LVs). In particular, host antiviral factors referred to as restriction factors targeting the retroviral life cycle can hamper LV transduction efficiency. Furthermore, LVs may activate innate immune sensors not only in differentiated hematopoietic cells but also in HSPCs, with potential consequences on transduction efficiency as well as their biological properties. Therefore, better understanding of the vector-host interactions in the context of hematopoietic gene transfer is important for the development of safer and more efficient gene therapy strategies. In this review, we briefly summarize the current knowledge regarding innate immune recognition of lentiviruses in primary human hematopoietic cells as well as discuss its relevance for LV-based ex vivo gene therapy approaches.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057370829

Download citation: RISBibTeXText

PMID: 25808164

DOI: 10.1089/hum.2015.036


Related references

Cyclosporine H Overcomes Innate Immune Restrictions to Improve Lentiviral Transduction and Gene Editing In Human Hematopoietic Stem Cells. Cell Stem Cell 23(6): 820-832.E9, 2018

Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody. Journal of Virology 84(13): 6645-6653, 2010

Restriction of HIV-1-based lentiviral vectors in adult primary marrow-derived and peripheral mobilized human CD34+ hematopoietic stem and progenitor cells occurs prior to viral DNA integration. Retrovirology 13(): 14-14, 2016

Lentiviral vectors escape innate sensing but trigger p53 in human hematopoietic stem and progenitor cells. Embo Molecular Medicine 9(9): 1198-1211, 2017

HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. Journal of Immunology 169(11): 6361-6368, 2002

The new self-inactivating lentiviral vector for thalassemia gene therapy combining two HPFH activating elements corrects human thalassemic hematopoietic stem cells. Human Gene Therapy 23(1): 15-31, 2012

Cellular restriction targeting viral capsids perturbs human immunodeficiency virus type 1 infection of nondividing cells. Journal of Virology 83(19): 9835-9843, 2009

Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy. Proceedings of the National Academy of Sciences of the United States of America 95(19): 11377-11382, 1998

Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectors. Journal of Biotechnology 156(3): 218-226, 2012

Dendritic cells and HIV infection; immunity with viral transmission versus compromised cellular immunity?. Immunobiology 204(5): 614-621, 2002

Development of gene therapy for hematopoietic stem cells using lentiviral vectors. Leukemia 16(4): 563-569, 2002

Vectofusin-1, a New Viral Entry Enhancer, Strongly Promotes Lentiviral Transduction of Human Hematopoietic Stem Cells. Molecular Therapy — Nucleic Acids 2(5): e90, 2013

High-efficiency lentiviral transduction of primary human CD34⁺ hematopoietic cells with low-dose viral inocula. Biotechnology Letters 37(2): 281-288, 2015

Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy. Biology of Blood and Marrow Transplantation 16(1 Suppl): S97-S105, 2010

Retrovirus-mediated gene transfer of human pyruvate kinase (PK) cDNA into murine hematopoietic cells: implications for gene therapy of human PK deficiency. Blood 83(8): 2305-2310, 1994